{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-312391","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-07-22T20:05:19+00:00","discovered_at":"2026-07-22T20:06:01.283937+00:00","generated_at":"2026-07-22T20:06:07.446741+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tempest partners with Senlang to develop TPST-4003 in vivo CAR-T; IIT in China expected Q4 2026","bullets":["Collaboration with Hebei Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T candidate.","First-in-human IIT in ~10 patients with myasthenia gravis or multiple sclerosis; first dosing Q4 2026.","Development fee range $1.5M-$2.0M per product; Senlang gets exclusive option for China rights.","Initial safety and PD data expected first half 2027.","Tempest retains all IP; Senlang will conduct trial in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-312391","json":"https://secwatch.observer/filing/0001193125-26-312391.json","markdown":"https://secwatch.observer/filing/0001193125-26-312391.md","text":"https://secwatch.observer/filing/0001193125-26-312391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/0001193125-26-312391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/d107304d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T20:06:07.446741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}